Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Ahead
scheduled · today and tomorrow · calendar refreshed 2026-10-12
Boeing, RTX Win $766 Mil In B-52 Modernization Contracts, Northrop Tapped For Deep Space Radar
Boeing and RTX won a combined $766 million in B-52 modernization contracts, and Northrop Grumman received an award tied to a deep space radar program. The report does not break out individual dollar amounts per contractor.
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Roche received FDA approval for companion diagnostic tests used to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who are eligible for ZIIHERA.